Author Archives: Bill Marshall

About Bill Marshall

CEO of Miragen

Nucleic Acid Therapeutics: Don’t Hit the Panic Button
November 28, 2016

This blog was written by both Bill Marshall, CEO of MiRagen Therapeutics, and Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Recent news from Alnylam, Ionis, and Mirna Therapeutics regarding toxicity-related setbacks

Leave a comment

Outliers: A Perspective On Startup Biotech Outside The Mega-clusters
February 3, 2016

This blog was written by Bill Marshall, CEO of MiRagen Therapeutics in Boulder, CO, as part of the “From The Trenches” feature of LifeSciVC. defines “outlier” as: (1) something that lies outside the main body or group that it


Storming The Beach: De-risking Novel Modalities Through Innovative Translational Medicine
July 21, 2015

This blog was written by Bill Marshall, co-founder and CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. microRNAs are an exciting new class of gene regulatory molecules that act on systems biology, and their modulation

Leave a comment

Nucleic Acid Therapeutics Coming of Age
April 1, 2015

This blog was written by Bill Marshall, CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The opportunity to use nucleic acids as therapeutic agents is extremely exciting. Creating drugs that affect protein targets that are

Leave a comment

It’s the People, Stupid:  Building and Maintaining a High Performance Corporate Culture
November 25, 2014

Building a performance based corporate culture is a key aspect of the biotech innovation business.  It can be easy to overlook this facet of company building as one focuses on determining the robustness of the new technology, refining your business

Leave a comment

Advancing A New Drug Modality: A Few Lessons Learned
August 21, 2014

Translating breakthrough science into breakthrough medicines is a daunting task.  It’s also worth every nail-biting minute waiting for the next result that brings you closer to helping a patient in need.  We started miRagen based on some amazing laboratory results

Leave a comment

A Tale of Disruptive Science, Irreproducibility, and Unanticipated Consequences
June 13, 2014

I’ve spent a significant amount of my career focused on the use of nucleic acids as therapeutic agents.  The ability of nucleic acids to act through exquisitely selective binding to other nucleic acids, proteins or other biologically active molecules provides

1 Comment

Encouraging Biotech Innovation
March 31, 2014

Let’s face it, biotech entrepreneurs are innovation junkies.  We desperately want to deploy the most novel technologies to solve difficult problems in medicine and deliver new, life changing medicines for patients who need our help.  Independent of additional factors that

Leave a comment